237 related articles for article (PubMed ID: 16504510)
41. Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy.
Vergote I; Robertson JF; Kleeberg U; Burton G; Osborne CK; Mauriac L; ;
Breast Cancer Res Treat; 2003 May; 79(2):207-11. PubMed ID: 12825855
[TBL] [Abstract][Full Text] [Related]
42. Aromatase inhibitors and breast cancer.
Miller WR
Minerva Endocrinol; 2006 Mar; 31(1):27-46. PubMed ID: 16498362
[TBL] [Abstract][Full Text] [Related]
43. Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of breast cancer.
Buzdar AU; Robertson JF
Ann Pharmacother; 2006 Sep; 40(9):1572-83. PubMed ID: 16912252
[TBL] [Abstract][Full Text] [Related]
44. Case studies of fulvestrant ("Faslodex") in postmenopausal women with advanced breast cancer.
Abram P; Maass N; Rea D; Simon SD; Steger GG
Cancer Treat Rev; 2005; 31 Suppl 2():S17-25. PubMed ID: 16199128
[TBL] [Abstract][Full Text] [Related]
45. Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer.
Scott SM; Brown M; Come SE
Expert Opin Drug Saf; 2011 Sep; 10(5):819-26. PubMed ID: 21699443
[TBL] [Abstract][Full Text] [Related]
46. Endocrine therapy--current benefits and limitations.
Nicholson RI; Johnston SR
Breast Cancer Res Treat; 2005; 93 Suppl 1():S3-10. PubMed ID: 16247594
[TBL] [Abstract][Full Text] [Related]
47. Fulvestrant ('Faslodex')--a new hormonal treatment for advanced breast cancer.
Lynn J
Eur J Oncol Nurs; 2004; 8 Suppl 2():S83-8. PubMed ID: 15590319
[TBL] [Abstract][Full Text] [Related]
48. Endocrine therapy for advanced/metastatic breast cancer.
Schiavon G; Smith IE
Hematol Oncol Clin North Am; 2013 Aug; 27(4):715-36, viii. PubMed ID: 23915741
[TBL] [Abstract][Full Text] [Related]
49. Is fulvestrant more effective than tamoxifen for treating ER-positive breast cancer in postmenopausal women?
Raina V
Nat Clin Pract Oncol; 2004 Nov; 1(1):20-1. PubMed ID: 16264793
[No Abstract] [Full Text] [Related]
50. Fulvestrant revisited: efficacy and safety of the 500-mg dose.
Howell A; Sapunar F
Clin Breast Cancer; 2011 Aug; 11(4):204-10. PubMed ID: 21729658
[TBL] [Abstract][Full Text] [Related]
51. Role of fulvestrant in sequential hormonal therapy for advanced, hormone receptor-positive breast cancer in postmenopausal women.
Come SE; Borges VF
Clin Breast Cancer; 2005 Apr; 6 Suppl 1():S15-22. PubMed ID: 15865846
[TBL] [Abstract][Full Text] [Related]
52. Fulvestrant ('Faslodex')--a new treatment option for patients progressing on prior endocrine therapy.
Morris C; Wakeling A
Endocr Relat Cancer; 2002 Dec; 9(4):267-76. PubMed ID: 12542403
[TBL] [Abstract][Full Text] [Related]
53. Fulvestrant ('Faslodex'): current and future role in breast cancer management.
Howell A
Crit Rev Oncol Hematol; 2006 Mar; 57(3):265-73. PubMed ID: 16473018
[TBL] [Abstract][Full Text] [Related]
54. ICI 182,780 (Fulvestrant)--the first oestrogen receptor down-regulator--current clinical data.
Robertson JF
Br J Cancer; 2001 Nov; 85 Suppl 2(Suppl 2):11-4. PubMed ID: 11900210
[TBL] [Abstract][Full Text] [Related]
55. Fulvestrant for the treatment of advanced breast cancer in postmenopausal women: a Japanese study.
Watanabe T; Sano M; Ohno S; Inaji H; Nishimura R; Shin E; Nomura Y; Morris C
Anticancer Res; 2004; 24(2C):1275-80. PubMed ID: 15154660
[TBL] [Abstract][Full Text] [Related]
56. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00).
Perey L; Paridaens R; Hawle H; Zaman K; Nolé F; Wildiers H; Fiche M; Dietrich D; Clément P; Köberle D; Goldhirsch A; Thürlimann B
Ann Oncol; 2007 Jan; 18(1):64-69. PubMed ID: 17030543
[TBL] [Abstract][Full Text] [Related]
57. Metastatic breast cancer: sequencing hormonal therapy and positioning of fulvestrant.
Vergote I; Amant F; Leunen K; Van Gorp T; Berteloot P; Neven P
Int J Gynecol Cancer; 2006; 16 Suppl 2():524-6. PubMed ID: 17010064
[TBL] [Abstract][Full Text] [Related]
58. Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer.
Piccart M; Parker LM; Pritchard KI
Ann Oncol; 2003 Jul; 14(7):1017-25. PubMed ID: 12853342
[TBL] [Abstract][Full Text] [Related]
59. Aromatase inhibitors in the breast cancer clinic: focus on exemestane.
Van Asten K; Neven P; Lintermans A; Wildiers H; Paridaens R
Endocr Relat Cancer; 2014 Feb; 21(1):R31-49. PubMed ID: 24434719
[TBL] [Abstract][Full Text] [Related]
60. Fulvestrant: a new type of estrogen receptor antagonist for the treatment of advanced breast cancer.
Buzdar AU
Drugs Today (Barc); 2004 Sep; 40(9):751-64. PubMed ID: 15538548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
